Vaxil BioTherapeutics Ltd.

vaxil-bio.com

High-Tech Company
Public Company

(TSX: VXL)

TECH VERTICALS

Biotechnology, MedTech, Therapeutics

General Data

Sector	Biomed
Company Stage:	R&D
Established	2006
Number of Employees	5
Reg. Number:	abCDe

DESCRIPTION

Vaxil Bio is an immunotherapy biotech company focused on a novel approach to targeting prominent cancer markers. Its lead product Immucin™ is a MUC1 signal peptide-derived product, wholly owned by Vaxil and protected by a series of patents in all major territories around the globe. As recently presented by the company, the mode of action by which Immucin™ exerts its unique immunological and clinical activity, is believed to be via its distinctive characteristics as a neoantigen. The Company has previously successfully completed a Phase- I/II clinical trial in multiple myeloma patients, after which Immucin™ was designated Orphan Drug by both the US FDA and the EMA for that indication. Vaxil is currently advancing toward clinical studies in additional solid tumor indications.

TECHNOLOGY

Vaxil's primary immunotherapy product is the ImMucin signal peptide cancer vaccine, which demonstrated very encouraging results in a Phase I/II study on 15 Multiple Myeloma patients. All the patients treated displayed a specific and robust immune response and 11 out of the 15 patients also derived clinical benefit. A small group of patients were followed post treatment with some patients continuing to derive clinical benefit for periods of several years post-treatment. Vaxil's ImMucin has also received Orphan Drug Status from both the FDA (June 2015) and EMA (March 2015).

Vaxil is currently in the process of planning and preparing its submissions to the regulator to receive approval for a larger Phase II study with ImMucin in Multiple Myeloma patients. More recently, Vaxil signed a preliminary agreement to collaborate with the Mayo Clinic which would see ImMucin tested as a combination therapy together with immunotherapeutic products and technology under development by the Mayo Clinic.

Products and Phases

Product	Phase
ImMucin	Phase II
ImMucin is a 21mer synthetic vaccine composed of the entire signal peptide domain of the MUC1 protein. ImMucin is intended to stimulate the patient's own immune system to control cancer by means of reacting to the natural corresponding MUC1 antigen as expressed on the surface of cancer cells.
MTbuVax	Phase I
Vaxil used its VaxHit technology to identify MTbuVax, a new class of synthetic T cell subunit vaccine against the pathogenic bacteria Mycobacterium Tuberculosis (Mtb). The vaccine contains a large antigenic repertoire from few high-quality targets, some of which are known antigens and others of which have been identified for this purpose using our technology.
ImBryon
BAGE1- positive tumors.
SPmAb2	Phase I
SPmAb2 is one of the promising anti-cancer targets known today and its association with cancer progression has been documented for the past two decades. MUC1 is a high-molecular-weight glycoprotein having few isoforms encoding both a transmembranal (i.e. across the cell membrane) and its cleavage truncated secreted (soluble) product. Both forms are expressed by more than 90% of solid epithelial tumor cancers as well as most common non-solid tumors including multiple myeloma. Improtently MUC1 is also expressed on cancer stem cells which are a key driver in the formation of tumor metastasis. MUC1 was recenty listed by the National Cancer Institute (NCI) pilot project the second most promising target from a list of 75 potential targets based on a number of ranked criteria required of an optimal cancer vaccine candidates.
SPmAb6	Phase I
First ever SP-specific antibodies & far more specific against targets.

	TARGET MARKETS
	Bio-Pharmaceutical Companies.

	BUSINESS MODEL
	B2B

CONTACT INFO

Expand / Collapse All

Main Address: Rehovot, Israel

Address	3 Pinhas Sapir Street, 3rd Floor, Weizmann Science Park
City	Rehovot
Country	Israel
Zip	74140

Contact Person	abC Defghij
Company E-mail	abC Defghij
Telephone	abC Defghij
Fax	abC Defghij

Branch Address: Toronto, Canada

Address	100 King W St., First Canadian Place, 34th Floor
City	Toronto
Country	Canada
Zip	M2N 6N4

Contact Person	abC Defghij
Company E-mail	abC Defghij
Telephone	abC Defghij
Fax	abC Defghij

	MANAGEMENT

Key Executive

Name	Title	Previous Position
Mr. Gadi Levin	CFO	Virtual Crypto (CFO)
Mr. Julian Levy	Co-Founder	BioKine (CEO)
Dr. Lior Carmon	Co-Founder	CBI (VP, Technology Assessment & Strategic Alliances)

	BOARD

Board

Member	Title	Affiliation
abC Defghij	Chairman	N\A

Mergers & Acquisitions

Round

Date

Stage

Amount

Valuation

Reverse Merger

Mar. 10, 2016

R&D

abCDe

Reverse Merger

Jun. 17, 2012

R&D

abCDe

Vaxil shareholders received 70% of Sheldonco, which fully owns Vaxil, and the holding could increase to 80%, subject to milestones. 2016: Delisted from TASE following reverse merger with Canadian shell company, Emerge Resources and beginning of trade on TSX.

* New investor

Investor	Type	Amount	Remarks
abC Defghij*	Holding Company	abCDe

	FINANCIAL ROUNDS

Total Capital Raised
abCDe

Financial Rounds

Numbers of Investors

Expand / Collapse All

Round

Date

Stage

Amount

Valuation

PIPE

Jul. 10, 2013

R&D

abCDe

	R&D Grants

Expand / Collapse All

Round

Date

Stage

Amount

Remarks

R&D Grant

Nov. 10, 2013

R&D

abCDe

* New investor

Investor	Type	Amount	Remarks
abC Defghij	Bi-Lateral R&D Program	abCDe

Last Updated:	abCDe
IVC Number:	abCDe